Global nutrition company Nutritional Growth Solutions (ASX:NGS) reports it has commenced a pilot clinical trial to evaluate the effect of its sport supplement on the physical activity performance of young soccer players.
The company says the clinical trial will be randomised, double-blind, placebo-controlled pilot that will recruit up to 50 healthy soccer players aged from 8 to 15, to determine the efficacy and safety of the new supplement versus placebo.
Nutritional Growth Solutions (NGS) reports the clinical trial comprises an 8-week treatment period followed by an 8-week open-label period with initial results expected in Q3 2023.
“This trial marks our first step into the growing sports supplements market”
Nutritional Growth Solutions Chief Executive Officer (CEO) and Managing Director Liron Fendell says: “This trial marks our first step into the growing sports supplements market, and we look forward to offering active children a safe, effective supplement, which was designed especially for them.
The global sports nutrition market and supplements was valued at US$44.43 billion in 2021 and is expected to increase in value to US$85.7 billion by 2030.
Based on extensive research, NGS has formulated an innovative nutritional supplement, aimed at completion of the high nutritional requirements of adolescent athletes to help them improve their body composition, exercise performance and general health.”
In the current trial, the company will run multiple tests including 10m and 20m sprints, countermovement jumps, agility tests, endurance tests, anthropometric assessments (height, weight and BMI), and body composition.
NGS says its nutritional supplement provides a boost of nutritious energy, and contains ‘high-quality’ whey proteins, additional specific amino acids, creatine monohydrate, carbohydrates, fats, and micronutrients (including calcium, iron, zinc, magnesium, vitamin A, vitamin C, vitamin D, vitamin E, and vitamin B complex).
Fendell says: “While sales of our existing products in the US continues to be our focus in 2023, we will invest up to $100k in this clinical trial, thus continuing to build a strong pipeline of innovative, exciting products which we could sell through our existing and additional distribution channels in 2023.
We’re looking forward to updating the market on both additional sales in the US and internationally as well as on the progress of the clinical trials over the coming weeks.”
Furthermore, the company notes research has shown that lacking sufficient calories, macro and micro-nutrients can impair an athlete’s training adaptations, while athletes who consume a balanced diet that meets energy needs can enhance physiological training adaptations.
Nutritional Growth Solutions is a global nutritional health company focused on the wellbeing of children. The company develops, produces and sells clinically tested supplements for children following 20 years of research into paediatric nutrition at Schneider Children’s Medical Centre in Israel.
